key: cord-0809463-ifpo9k9b
authors: Wang, Qian‐Chen; Wang, Zhen‐Yu
title: Continuous focus on COVID‐19 epidemic: Changes in China’s clinical guidance
date: 2020-12-16
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13869
sha: 98b60602bddeb9b51c1d6e20fa076022f3513d03
doc_id: 809463
cord_uid: ifpo9k9b

BACKGROUNDS: The epidemic of coronavirus disease 2019 (COVID‐19) is spreading across the world. As the first country who suffered from the outbreak, China has been taking strict and effective measures to contain the epidemic and treat the disease under the instruction of updating guidance. AIMS: To compare the changes and updates in China's clinical guidance for COVID‐19. METHODS: We explored China's experience in dealing with the epidemic by longitudinal comparison of China's clinical guidance for COVID‐19. RESULTS: As of March 4, there are 7 editions of the guidance. With the increasing understanding of COVID‐19, changes have been made in aetiology, epidemiology, pathology, clinical features, diagnostic criteria, clinical classification, and treatment. CONCLUSIONS: We have made a summary of the changes and updates in China's clinical guidance for COVID‐19, which mirrors the deepening understanding of the disease over the course of fighting it, hoping to help clinicians worldwide.

The pathogen of COVID-19 is constantly being recognised. In the first three editions, we only knew that it was a novel coronavirus.

The description of the coronavirus aetiology was based on the previous physicochemical understanding of coronavirus. With the study of the full-length genomic sequence of the virus, 2 the characteristics of the pathogen were refined in the 4th edition.

The novel coronavirus (termed as SARS-CoV-2 by the International Committee on Taxonomy of Viruses) shares more than 85% homology with SARS-like coronavirus isolated from the bat (bat-SL-CoVZC45). 3 SARS-CoV-2 can be inactivated by ultraviolet, heat (56°C for 30 minutes), 75% ethanol (w/v), chlorine-containing disinfectant, and chloroform.

With the increase in the cases of COVID-19 and the progress of epidemiological research, since the 4th edition of the guidance, the epidemiological characteristics of COVID-19 have been specifically listed, including the source of infection, the route of transmission, and the susceptible population (See Table 1 ).

On February 17, Fusheng Wang et al 4 reported the pathological findings of COVID-19, which showed bilateral diffuse alveolar damage with hyaline membrane formation and peripheral blood T cells over-activation, indicating that the disease mainly damages lung 

As an important lung disease examination method, chest CT plays an important role in the diagnosis of COVID-19, 5, 6 and it is also an important indicator for judging and detecting the change in the patient's condition, guiding the treatment, and predicting the development of the disease. Considering that false negatives in nucleic acid testing can lead to misdiagnosis, clinicians recommend that CT be included as a screening tool. Since the 3rd edition of the guidance, the CT characteristics of COVID-19 were clarified.

The diagnostic criteria of COVID-19 mainly include epidemiological history, clinical manifestations, and aetiological evidence. In the 7th edition of the guidance, suspected cases with one of the following aetiological or serological evidence can be identified as 

The clinical classification of disease types is conducive to effective case management thus improving the cure rate. COVID-19 clinical classification has been gradually improved since the 3rd edition of guidance. A comparison of clinical classification amongst editions is listed in Table 2 .

Antiviral therapy, including Interferon-α inhalation, Lopinavir/ Ritonavir, Chloroquine phosphate, Arbidol, and Ribavirin are recommended in the 7th edition of guidance. The treatment for COVID-19

has been continuously updating. Table 3 concludes the changes in antiviral therapy amongst editions. It is not recommended to use three or more antiviral drugs at the same time. The course of treatment should be less than 10 d. Related medications should be stopped on the occurrence of intolerable side effects.

For the treatment of pregnant women, the weeks of pregnancy should be considered, and medication should be as less influential to foetus as possible. Informed consent is required if the termination of pregnancy is needed.

China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease in China

Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection